Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746753 · ClinicalTrials.gov registry record · Phase 4
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT06746753: Clinical Trial Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT06746753 is a Phase 4 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 78 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06746753, a Phase 4 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Primary Outcome
Mean plasma renin level (PRA) as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin \<1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock.
Interventions
- DRUG Norepinephrine
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-10-07 |
| Phase | Phase 4 |
What is known before NCT06746753 opens enrollment
NCT06746753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Norepinephrine is the first listed.
NCT06746753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06746753 about?
NCT06746753 is a clinical study titled "Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock". Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are...
What is the current status of trial NCT06746753?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2026-07. Estimated completion is 2028-10-07.
What interventions are being tested in trial NCT06746753?
The interventions under investigation include: Norepinephrine (DRUG), Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT06746753?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06746753's enrollment target sits among peer trials
78 982nd of 2000 higher than 1,012 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia